EU notified bodies trained in Taiwanese regulations:
This article was originally published in Clinica
As Clinica went to press, the European Commission unit responsible for medical devices was due to receive on April 7-8 a delegation from the Chinese Taipei which is visiting Brussels to train EU notified bodies in the Chinese Taipei medical device regulatory system. This is part of a trade agreement between the Chinese Taipei and the EU, which, although not an MRA, has been described as the nearest thing to one (see Clinica No 1149, p 3). An EU delegation is due to go to the Chinese Taipei either in November 2005 or November 2006.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.